v3.26.1
Segment Performance Measures and Expenses (Tables)
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Schedule of Significant Expense Categories and Consolidated Net Loss

The table below provides a summary of the significant expense categories and consolidated net loss details provided to the CODM (in thousands):

 

               
   For the six months ended June 30, 
   (In thousands)   Change Increase (Decrease) 
   2026   2025         
Operating Expenses:                    
Clinical Research                    
OVATION Trials (Phase 2 & 3)  $347   $309   $38    12.3%
MRD Study   96    73    23    31.5%
PlaCCine Vaccine Phase 1 Trial   -    83    (83)   (100.0)%
Other Clinical and Regulatory   929    901    28    3.1%
Subtotal   1,372    1,366    6    0.4%
Non-Clinical R&D and CMC                    
Manufacturing & Clinical Supply   2,430    2,026    404    19.9%
Subtotal   2,430    2,026    404    19.9%
                     
Research and development expenses   3,802    3,392    410    12.1%
General and administrative expenses   3,296    3,521    (225)   (6.4)%
Total operating expenses   7,098    6,913    185    2.7%
                     
Loss from operations  $(7,098)  $(6,913)  $(185)   (2.7)%